IBIO, INC. Income (Loss) from Continuing Operations, Per Diluted Share
IBIO, INC. (IBIO) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$1.75 per share for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2025-09-05
- IBIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-03-31 was -$0.49.
- IBIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2024-12-31 was -$0.48.
- IBIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2024-09-30 was -$0.46.
- IBIO, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2024-03-31 was -$0.71.
- IBIO, INC. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$1.75.
- IBIO, INC. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$4.03.
- IBIO, INC. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$47.88.
- IBIO, INC. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$3.39.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 12 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -$1.75 10-K · filed 2025-09-05 | |||||||
| 2025-03-31 | -$0.49 10-Q · filed 2025-05-02 | -$1.44 10-Q · filed 2025-05-02 | ||||||
| 2024-12-31 | -$0.48 10-Q · filed 2025-02-10 | -$0.94 10-Q · filed 2025-02-10 | ||||||
| 2024-09-30 | -$0.46 10-Q · filed 2024-11-12 | |||||||
| 2024-06-30 | -$4.03 10-K · filed 2025-09-05 | |||||||
| 2024-03-31 | -$0.71 10-Q · filed 2025-05-02 | -$5.43 10-Q · filed 2025-05-02 | ||||||
| 2023-12-31 | -$2.42 10-Q · filed 2025-02-10 | -$6.27 10-Q · filed 2025-02-10 | ||||||
| 2023-09-30 | -$4.24 10-Q · filed 2024-11-12 | -$0.21 10-Q · filed 2023-11-14 | ||||||
| 2023-06-30 | -$47.88 10-K/A · filed 2024-09-24 | -$2.39 10-K · filed 2023-09-27 | ||||||
| 2023-03-31 | -$9.53 10-Q · filed 2024-05-13 | -$0.47 10-Q · filed 2023-05-15 | -$46.00 10-Q · filed 2024-05-13 | -$2.30 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | -$21.54 10-Q · filed 2024-02-09 | -$1.08 10-Q · filed 2023-02-14 | -$38.82 10-Q · filed 2024-02-09 | -$1.94 10-Q · filed 2023-02-14 | ||||
| 2022-09-30 | -$0.85 10-Q · filed 2023-11-14 | |||||||
| 2022-06-30 | -$3.39 10-K · filed 2023-09-27 | |||||||
| 2022-03-31 | -$0.77 10-Q · filed 2023-05-15 | -$2.20 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | -$0.83 10-Q/A · filed 2023-05-19 | -$1.43 10-Q/A · filed 2023-05-19 | ||||||
| 2021-09-30 | -$1.43 10-Q/A · filed 2023-05-19 | -$0.60 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |